- Details
- Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO, show...
|
- Details
- Zach Klaassen and Gautam (Tom) Jayram explore the use of blue light cystoscopy in bladder cancer. Dr. Jayram explains its mechanism, where an optical agent, interacting with the heme biosynthetic pathway, causes cancer cells to accumulate photo porphyrins that light up under specific wavelengths. This technology is crucial for patients suspected of having or with a history of bladder cancer, enhan...
|
- Details
- Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic virus targeting cells with retinoblastoma pathway defects, common in cancer cells. This treatment, when instilled in the bladder, prompts immune cells to destroy cancer cells. Highlighted are several key trials: CORE-00...
|
- Details
- Siamak Daneshmand hosts Trinity Bivalacqua to discuss advancements in non-muscle invasive bladder cancer, particularly focusing on newly FDA-approved therapies. Dr. Bivalacqua highlights the excitement surrounding the approval of new treatments for BCG unresponsive bladder cancer, including pembrolizumab and nadofaragene (ADSTILADRIN). He explains the significance of these developments, particular...
|
- Details
- Zach Klaassen hosts Mark Tyson for a discussion on the noninvasive urinary genomic biomarker test, Cxbladder. Dr. Tyson explains that Cxbladder Detect assesses bladder cancer risk in patients with microscopic hematuria by analyzing urine for specific mRNA biomarkers. The test aims to reduce invasive diagnostics like cystoscopy, aligning with AUA guidelines for a risk-stratified approach. Their dec...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...
|
- Details
- Sam Chang and Sia Daneshmand explore the impact of Cysview blue light cystoscopy on cancer recurrence. Dr. Daneshmand presents a comprehensive registry study from USC which shows significantly lower recurrence rates in patients examined with blue light cystoscopy, when compared to a white light patient group. Notwithstanding potential variables like modern management techniques, they attribute thi...
|
- Details
- Siamak Daneshmand shares insights Phase 2 Study of the "Efficacy and Safety of Erdafitinib in Patients with Bacillus Calmette-Guérin-Unresponsive, High-Risk Non–muscle-Invasive Bladder Cancer with FGFR3/2 Alterations in THOR-2". For patients that present with NMIBC who have carcinoma in situ (CIS), there is a high risk of disease progression. In more advanced bladder cancer FGFR inhibition has dem...
|
- Details
- Ashish Kamat hosts Colin Dinney in a discussion on Adstiladrin Gene Therapy for BCG Unresponsive Disease, highlighting an unmet need for effective second-line therapies for patients suffering from non-muscle invasive bladder cancer. He reveals that the Adstiladrin Phase 3 trial showed promising results, with a complete response rate of 53% for carcinoma in situ (CIS) at three months. Citing its co...
|
- Details
- Sam Chang speaks with Tara Cumming and Meredith Donahue who share their insights on implementing an efficient system for administering instillation therapy for bladder cancer patients at Vanderbilt. Cumming and Donahue were instrumental in designing this streamlined process, which they call the BCG Clinic, where patients receive treatment one day each week, improving not just patient care but also...
|